MENINGOCOCCUS SEPTICEMIA

Meningococcus B

Between 13 different serogroups of N. meningitidis, identified according to the capsular polysaccharide’s antigenic structure, only 5 (A, B, C, W-135 and Y) are clinically relevant and responsible for 90% cases of meningococcal invasive disease. In Italy, serogroup B is the principal cause of invasive meningococcal disease [1]. There are two types of tetravalent vaccines for serogroups A, C, W-...

Studies on Meningococcus Infection

Precipitin tests, carried out on the cerebrospinal fluid from cases of meningococcal meningitis with monovalent sera, demonstrate the presence in that fluid of type-specific precipitinogens of the meningococcus. Negative results are secured when the spinal fluid is obtained after the commencement of intrathecal serum treatment and also occasionally when the numbers of infecting organisms are ve...

The meningococcus tamed?

Serogroup B Neisseria meningitidis is a frequent cause of invasive meningococcal disease, yet there are no effective vaccines suitable for routine immunisation. Limited efficacy has been shown with meningococcal outer membrane vacccines in children 4 years and older. Here we review the status of current research and consider new approaches to development of meningococcal serogroup B vaccines.

Immunisation against meningococcus B.

www.thelancet.com Vol 382 September 7, 2013 857 in 2000 under circumstances of uncertainty about efficacy and low (but in that case rising) disease incidence. A decision to introduce the Novartis vaccine, which is not really a meningococcus B but actually a broader, generic meningococcal vaccine, and to give it to adolescents and young adults who have the highest carriage rates could have been ...

Growth Requirements of the Meningococcus.